OnabotulinumtoxinA (Botox) clinical coverage criteria
Defines medical necessity criteria, initial and continuation approval requirements, dose limits, age limits, prescriber requirements, contraindications, and approval durations for onabotulinumtoxinA (Botox) across multiple FDA-approved and selected off-label indications for Commercial, HIM and Medicaid lines of business.
No material clinical/coverage changes.
Coverage Summary
OnabotulinumtoxinA (Botox) is a neuromuscular blocking agent and acetylcholine release inhibitor indicated for multiple neurologic, urologic, dermatologic, ophthalmologic and gastrointestinal conditions. The policy defines medical necessity criteria aligning FDA-approved uses with Centene-specific initial and continuation requirements and dose limits. Coverage stance: covered_with_criteria — Botox is authorized when indication-specific criteria (including prescriber specialty, age limits, prior therapy where required, documentation of treatment plan and unit limits, and intervals since prior botulinum toxin) are met. The scope applies across Commercial, HIM and Medicaid lines of business and includes FDA-approved indications plus select off-label uses with supporting evidence requirements.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.